Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.00B | 1.12B | 971.52M | 733.38M | 477.81M | Gross Profit |
160.03M | 141.97M | 90.55M | 110.54M | 98.31M | EBIT |
67.10M | 47.55M | 10.15M | 35.95M | 50.75M | EBITDA |
101.90M | 89.75M | 48.75M | 74.02M | 105.70M | Net Income Common Stockholders |
19.87M | 26.62M | 3.43M | 24.36M | 64.03M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
0.00 | 0.00 | -28.09M | -25.07M | -26.08M | Total Assets |
524.89M | 607.09M | 611.40M | 531.55M | 513.52M | Total Debt |
85.13M | 117.30M | 122.14M | 90.39M | 111.45M | Net Debt |
85.13M | 117.30M | 150.23M | 115.46M | 137.53M | Total Liabilities |
245.94M | 320.07M | 324.42M | 227.20M | 212.55M | Stockholders Equity |
278.55M | 286.83M | 286.79M | 304.38M | 299.15M |
Cash Flow | Free Cash Flow | |||
40.49M | 59.89M | 56.86M | 56.70M | 67.82M | Operating Cash Flow |
66.92M | 80.55M | 63.99M | 64.49M | 72.81M | Investing Cash Flow |
6.82M | -24.05M | -49.84M | -7.99M | -2.36M | Financing Cash Flow |
-73.74M | -56.50M | -14.15M | -56.49M | -73.03M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | C$758.76M | 23.67 | 6.73% | ― | 4.84% | 67.68% | |
63 Neutral | C$448.99M | 23.23 | 13.20% | 4.85% | -10.24% | -23.79% | |
62 Neutral | $8.16B | 12.85 | 0.64% | 3.04% | 3.83% | -15.83% | |
61 Neutral | C$1.92B | 22.99 | 9.36% | 1.71% | 2.49% | -22.94% | |
51 Neutral | C$1.13B | ― | -5.87% | 4.21% | -8.64% | -136.62% |
Dexterra Group Inc. has announced the release of its Q4 2024 financial results scheduled for March 6, 2025, after market close, with a subsequent conference call and webcast on March 7, 2025. This announcement is significant as it reflects Dexterra’s ongoing commitment to transparency and communication with stakeholders, potentially impacting its market positioning and stakeholder relations positively.